Who is sponsoring NCT03266848?

NCT03266848 is sponsored by Theranano LLC.

What drugs are being tested in NCT03266848?

Interventions in NCT03266848: Quantitative Magnetic Resonance Imaging.

What condition does NCT03266848 study?

NCT03266848 studies Cerebrovascular Disorders.

Is NCT03266848 still recruiting?

NCT03266848 is currently completed. Last updated 24 August 2021.

Last reviewed 2021-08-24 · How we verify

NCT03266848

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quantitative Non-Invasive Brain Imaging Using QUTE-CE MRI

Completed Last updated 24 August 2021

What this trial tests

trial testing Quantitative Magnetic Resonance Imaging in Cerebrovascular Disorders in 15 participants. Completed in 22 July 2020.

Timeline

8 November 2017

Primary endpoint
22 July 2020

22 July 2020

Quick facts

Lead sponsor	Theranano LLC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15
Start date	8 November 2017
Primary completion	22 July 2020
Estimated completion	22 July 2020
Sites	1 location across United States

Drugs / interventions tested

Quantitative Magnetic Resonance Imaging

Conditions studied

Cerebrovascular Disorders — all drugs for Cerebrovascular Disorders →

Sponsor

Theranano LLC

Who can join

Adults 18 to 80, any sex, with Cerebrovascular Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will evaluate a non-invasive brain imaging technique QUTE-CE MRI and validate the method with first-in-human studies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Trials of Thermosensitive Nanomaterials: An Overview.
Nardecchia S, Sánchez-Moreno P, Sánchez-Moreno P, Vicente J, et al · · 2019 · cited 60× · PMID 30717386 · DOI 10.3390/nano9020191
Super High Contrast USPIO-Enhanced Cerebrovascular Angiography Using Ultrashort Time-to-Echo MRI.
Timms L, Zhou T, Qiao J, Gharagouzloo C, et al · · 2024 · PMID 38644981 · DOI 10.1155/2024/9763364

Verify or expand the search:

Other recruiting trials for Cerebrovascular Disorders

Currently open trials in the same condition.

NCT07185022 — Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion · NA · recruiting
NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation · recruiting
NCT07167550 — The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke · Phase 3 · recruiting
NCT07140601 — Environmental Pollutants and Neurological Disorders · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03266848 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Theranano LLC
Last refreshed: 24 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03266848.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing